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SUMMARY

Although aneuploidy is found in the majority of
tumors, the degree of aneuploidy varies widely. It is
unclear how cancer cells become aneuploid or how
highly aneuploid tumors are different from those of
more normal ploidy. We developed a simple computational method that measures the degree of aneuploidy or structural rearrangements of large chromosome regions of 522 human breast tumors from The
Cancer Genome Atlas (TCGA). Highly aneuploid tumors overexpress activators of mitotic transcription
and the genes encoding proteins that segregate
chromosomes. Overexpression of three mitotic transcriptional regulators, E2F1, MYBL2, and FOXM1, is
sufficient to increase the rate of lagging anaphase
chromosomes in a non-transformed vertebrate
tissue, demonstrating that this event can initiate
aneuploidy. Highly aneuploid human breast tumors
are also enriched in TP53 mutations. TP53 mutations
co-associate with the overexpression of mitotic transcriptional activators, suggesting that these events
work together to provide fitness to breast tumors.
INTRODUCTION
Aneuploidy is a hallmark of cancer and is high in breast tumors.
Current estimates suggest that 90% of solid tumors contain
whole-chromosome gains or losses (Danielsen et al., 2016; Roylance et al., 2011). The amount of aneuploidy between tumors
and within a tumor is highly variable, suggesting that in addition
to current breast cancer classifications, the degree of aneuploidy
could be used to tailor treatments. However, classification of
tumors requires either simple assays to measure aneuploidy in
tumors or a deeper understanding of the mechanisms that drive
aneuploidy.
The fidelity of mitosis is critical in maintaining a normal
karyotype. Tumor cells sometimes lower the fidelity of mitosis
by unknown mechanisms to generate chromosomal instability
(CIN). It is estimated that 45% of breast tumors develop CIN,
while the rest remain karyotypically stable (Lingle et al., 2002;

Roylance et al., 2011). CIN could drive tumor evolution by driving
loss of heterozygosity (LOH) of tumor suppressors or by generating imbalances or structural changes that overexpress oncogenes. How tumor cells develop CIN is an important unanswered
question. Mutations in mitotic proteins can drive aneuploidy in
experimental systems; however, the major mitotic regulators
are rarely mutated in cancer (Bakhoum and Compton, 2012;
Bakhoum et al., 2009; Barber et al., 2008; Cahill et al., 1998,
1999).There are examples implicating known tumor suppressors
and oncogenes in driving CIN; for example, the overexpression
of cyclin D in mouse mammary tissue generates a CIN
phenotype and late-onset tumors. In addition, the Mad2 spindle
checkpoint protein is regulated by E2F and Rb1 and contributes
to their potent oncogenic roles (Casimiro and Pestell, 2012;
Schvartzman et al., 2011; van Deursen, 2007).
Mutations in the TP53 tumor suppressor are associated with
aneuploid tumors (Clark et al., 1992; Kihana et al., 1992), but there
is a debate about how it prevents aneuploidy. Current models
suggest that mutating TP53 does not lower the fidelity of mitosis;
however, cells that arrest in mitosis for an extended period
can trigger tp53 responses that senesce cells (Thompson and
Compton, 2010; Uetake and Sluder, 2010). In addition, the missegregation of chromosomes can also trigger a tp53 response,
although there is a current debate regarding whether this is an
immediate response or requires multiple cell divisions (Li et al.,
2010; Santaguida et al., 2017; Soto et al., 2017; Thompson and
Compton, 2010). Together, these data suggest that loss of tp53
function does not cause aneuploidy, but it is critical to allow
aneuploid cells to remain proliferative.
Transcription factors that regulate the transcription of genes
required for mitosis can be oncogenes or tumor suppressors
(Fischer et al., 2016). It is unclear how they provide a selective
advantage to tumor cells and drive tumor progression. The
MuvB transcription complex binds cell cycle promoters and associates with MYBL2 and FOXM1 in S-phase/G2 to activate the
promoters of a number of genes required for mitosis (Sadasivam
et al., 2012). Both MYBL2 and FOXM1 are oncogenes that are
overexpressed in a subset of breast tumors (Laoukili et al.,
2007). E2F1 drives the transcription of cell-cycle genes in G1
phase, and it plays critical roles in the cell’s ability to initiate proliferation, which is a well-established role in tumor development.
However, E2F1 also binds the promoters of many mitotic genes
that are transcribed in G2, and it is unclear whether this also
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contributes to its oncogenic potential (Cao et al., 2011). Interestingly, loss of the tumor suppressor Rb1, which inhibits the E2F1
transcription factor, is associated with aneuploidy (Manning and
Dyson, 2012). Meta-analysis of TP53 downregulated genes suggest that MYBL2, FOXM1, and E2F1 cell-cycle transcriptional
regulators are important targets of the tp53 response (Fischer
et al., 2016).
Measuring CIN requires knowing cell-to-cell variability in chromosome number and structure within a tumor or an assessment
of the rate at which chromosomal changes occur. Therefore, it is
more feasible to measure aneuploidy within tumors. Chromosomal changes can be measured by multigene fluorescent in
situ hybridization (FISH), comparative genomic hybridization
(CGH), and counting of anaphase lagging chromosomes, but
these are difficult to perform on biopsies (Bakhoum and
Compton, 2012; McGranahan et al., 2012). Therefore, neither
CIN nor aneuploidy is routinely tested in the clinic. An algorithm
to measure the consequences of CIN (changes in copy number
of whole or parts of chromosomes of dominant cell populations
within the tumor) was developed by comparing the overexpression of adjacent sets of genes along chromosomes in transcriptional array data (Carter et al., 2006). Carter et al. coined the term
‘‘functional aneuploidy’’ (FA) to distinguish the direct measurement of aneuploidy from CIN, which measures a rate of missegration. Several cell-cycle regulators were found in CIN tumors,
and they identified a CIN signature based on the top 70 genes
that were overexpressed in CIN tumors (CIN70) (Carter et al.,
2006). High expression of the top 25 of these genes indicates
poor prognosis in 12 studies and six different tumor types (Carter
et al., 2006). This report supported a number of other studies
where CIN was correlated with poor prognosis by either FISH
analysis or CGH (Chandhok and Pellman, 2009). There is an opportunity to learn more about how CIN develops by segregating
tumors by aneuploidy status in large well-annotated tumor databases such as The Cancer Genome Atlas (TCGA) (2012).
We developed a computational method for measuring aneuploidy and large structural changes of chromosomes from
exome sequence data based on the heterogeneity of allele
frequencies. This allowed us to segregate breast tumors from
the TCGA datasets based on their amount of aneuploidy. We
compared gene expression profiles from tumors with high and
low FA to identify the mechanisms that generate highly aneuploid
tumors. Our data confirm that there is a striking correlation between mutations in TP53 and FA in breast tumors (Pati et al.,
2004; Sigurdsson et al., 2000). Although the genes encoding
the proteins that segregate chromosomes were rarely mutated,
they dominate the proteins that are specifically overexpressed
in highly aneuploid tumors. In addition, regulators of mitotic transcription, MYBL2, E2F1, and FOXM1, were overexpressed in
highly aneuploid breast tumors. We expressed these oncogenes
in Xenopus embryos and followed the first divisions that are
driven by transcription to show the sufficiency of the overexpression of these three oncogenes to lower the fidelity of mitosis in
non-transformed vertebrate epithelial tissues. Our analysis of
human breast tumors suggests a two-hit model for generating
aneuploidy or CIN (although it cannot predict which hit comes
first). First, the overexpression of the E2F1, FOXM1, and
MYB2L oncogenes lowers the fidelity of chromosome segrega-

tion. Second, the loss of TP53 function enables cells that missegregate chromosomes to remain proliferative.
RESULTS
Measuring the Amount of Aneuploidy in Tumors from the
TCGA by Calculating the Variance of Allelic Frequency
Ratios
We developed a computational method to measure the amount
of aneuploidy in tumors. The method measures changes
in copy number of both whole chromosomes and large
fragments of chromosomes, which we refer to as FA (‘‘functional
aneuploidy’’), as originally termed in the CIN70 work (Carter
et al., 2006). Aneuploidy changes alternate allele frequencies
(AAFs), which can be measured using the exome sequence
data available for TCGA samples. AAF in a tumor is a function
of the chromosome number in each cell and the percentage of
cells that are aneuploid (Figure S1). We developed a simple pipeline to visualize the FA within a single human breast tumor using
publically available data from the TCGA consortium (Figure S2).
We identified all heterozygous SNPs for each patient as defined
by allele frequencies between 0.3 and 0.7 in the non-transformed
exome sequence reads. For each heterozygous SNP, we calculate the AAF in the tumor by dividing the number of sequence
reads that identify the alternate allele relative to the total number
of reads aligning to that genomic region. We plot histograms of
the number of SNPs per AAF for each patient’s tumor (Figure 1A;
Data S1). Tumors with minimal FA retained a single peak in the
histogram of heterozygous alleles that was normally distributed
between AAFs of 0.3 and 0.7, as is seen in all matched samples.
In contrast, the range of distributions broadens to include AAFs
between 0.1 and 0.9 in tumors whose heterogeneity is driven by
events that encompass large fragments or whole chromosomes,
since these change the AAF for thousands of SNPs (Figures 1A,
S1, and S2). A trimodal AAF distribution was found in many of the
tumor plots, even though they lack alleles that were homozygous
in the normal matched sample. These trimodal distributions arise
from LOH events that convert SNP ratios that were heterozygous
and close to 0.5 in the matched normal tissue to ratios that
appear near homozygous in the tumor.
The width of these AAF histograms correlates to the amount of
FA in each tumor. We measured the width of the peaks for 522
breast tumors of various grades and types from the TCGA dataset by calculating the SD of the allele frequency distribution of all
AAFs between 0.1 and 0.9 (Figure S3; Table S1). We decided on
this simple approach because it is robust and assumption-free.
We used these SDs to rank the tumors, assigning the tumor
with the widest peaks (largest SD) as number 1, while the tumor
with the narrowest peak (smallest SD) as number 522. Examples
of 10 tumors and their relative ranks are shown in Figure 1A. Note
that all the tumors ranked below 200 are qualitatively broader
than plots generated from matched normal sequence data
(compare Figure 1A to the corresponding plots of the normal
samples in Figure S4), while most of the tumors ranked above
300 were similar to plots generated from non-tumor sequence
datasets (Figure S4). Each of the tumors ranked below 200 has
its own characteristic shape and extent of AAF peak broadening,
which represents the amount of tumor heterogeneity. There is a
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continuum of AAF distributions (Figure S3). The histograms of the
115 highest FA scored tumors have both broad central peaks
as well as outer peaks from LOH (Data S1). Between 115 and
226, there are broad central peaks only. In the tumors ranked
from 227 to 320, the peaks transition between noticeable broadening and peaks that appear similar to the matched normal
samples. The final 200 tumors (321–522) resemble the matched
control plots, suggesting that they have low amounts of FA.
For each tumor, we also generated complementary plots that
show the chromosome position of each SNPs AAF score (Figures
1B and S2; Data S2). LOH events generate areas with few SNPs in
the 0.5 AAF regions, with corresponding dense areas of SNPs
scoring closer to zero and one. The AAF frequencies of most
SNPs are contiguous along whole chromosomes or large chromosome regions, confirming that aneuploidy and not random point
mutations drives the redistribution of AAF frequencies in tumor
samples (Figure 1B). We quantified the number of chromosomes
with a region of LOH that spanned a large region of a chromosome
(scoring method is outlined in Figure S5A; see also Figure 1C). Our
2760 Cell Reports 23, 2758–2769, May 29, 2018

Figure 1. Measuring the Aneuploidy
in Tumors by the Broadening of
Allelic Frequency Ratios Calculated from
Sequencing Data
(A) 10 examples of FA histograms, each portraying
the allelic frequencies of the heterozygous SNPs
of human breast tumors. The number in the top
right corner of each plot represents the FA ranking
based on the broadening of the allele frequency
peaks, with 1 being the widest peak and 510 the
narrowest peak. Note that the lower the number,
the broader the central peak of allelic frequencies.
(B) Replots of 5 of the tumors from (A) showing the
allele frequency ratios along chromosome positions corresponding to coordinates in the GRCh37
genome (so each chromosome runs p arm to q
arm). Note that the LOH events that separate the
central peaks into two often span large segments
of chromosomes or whole chromosomes, which is
consistent with chromosome missegregation
driving the LOH event.
(C) Plot of the frequency of whole (blue) or partial
(red) chromosome LOH for each chromosome.
(D and E) The number of chromosomes with an
LOH event in breast tumors correlates with the
ranking (D) and FA score (E) of the tumors. R2 values
were calculated by fitting to a second-order polynomial curve in Excel. Our method of LOH quantification is summarized in Figure S5.

analysis confirmed the high percentages
of LOH in chromosomes 11, 16, and 17
found in breast tumors (Lindblom et al.,
1993; Nagayama and Watatani, 1993),
which validates our analysis (Figure 1C).
We also found large amounts of LOH in
chromosomes 1 and 8. They were then injected with either control RNA or the RNA
encoding the three transcription factors
(FOXM1, E2F1, and MYBL2) in two of the
four cells of Stage 3 embryos (Figures 5E
and 5F). The tumors ranked lower than 200 showed a stronger
correlation of chromosomes with LOH events than the other 322
tumors, which is consistent with about 40% of breast tumors having strong CIN. Whole-chromosome events that are expected from
missegregation of chromosomes during mitosis were more
strongly represented in the tumors ranked 1–200 (R2 = 0.66; Figure S5B), while they were rare in the tumors ranked from 300 to
522. LOH along large regions of chromosomes, but not spanning
the entire chromosome, had similar distributions but were not as
tightly linked to our ranking (R2 = 0.53; Figure S5C). Together, these
analyses confirm that our method can segregate tumors by the
amount of aneuploidy of the cells within the tumor and also that
missegregation of whole chromosomes contributes to the FA of
high-ranking tumors.
Identification of the Mechanisms Generating FA in
Breast Tumors
We used the Variant Annotation, Analysis and Search Tool
(VAAST) (Yandell et al., 2011) to identify the genes that had higher
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Figure 2. Identification of Genes Mutated in Aneuploid Tumors
(A) Histogram showing the distribution of FA scores of the 522 analyzed human
breast tumors. The boxes highlight the distributions of the 100 highest and
lowest scoring tumors.
(B) The number of chromosomes with LOH events was compared in the 100
highest and lowest aneuploid tumors to demonstrate that the analysis stratifies
tumors by aneuploid status. The p value was generated by Welch two-sample
t test in R.
(C) All genes significantly mutated in the high aneuploid tumor sets were identified by comparing the sequence data from the 100 highest and lowest ranked
tumors using the VAAST program. The p values were calculated by VAAST.
(D) p53 mutations are correlated with functional aneuploidy in the 250 top
ranked tumors.

numbers of mutations in the 100 tumors with the highest FA score
compared to the 100 with the lowest FA score (dotted boxes in
Figure 2A). The average number of chromosomes with an LOH
event (whole or partial) in the two groups were 15.6 and 0.97,
respectively, demonstrating that we are segregating tumors by

FA status (Figure 2B). Mutations in TP53 were highly enriched in
the high FA tumors (p = 1.5 3 10 140; Figure 2C). TP53 mutations
have previously been connected to aneuploidy in tumors, validating our method (Li et al., 2010; Thompson and Compton,
2010). The strong association is consistent with a growing body
of literature arguing that tp53 arrests non-transformed cells in
G1 following a prolonged mitotic arrest or the missegregation of
a chromosome (Hayashi et al., 2012; Jeon and Lee, 2013; Krzywicka-Racka and Sluder, 2011; Uetake and Sluder, 2010). Forty
of the 50 tumors with the most FA contained TP53 mutations.
Interestingly, the percentage of tumors with TP53 mutations
decreased as a function of FA rank for the 250 tumors with
the most FA (linear-by-linear association test, test statistic =
30.21842; p = 3.86 3 10 8), and then there was poorer correlation
in the following 246 tumors that are likely to have low FA status
(test statistic = 1.222109; p = 2.689310–1) (Figure 2D) (Agresti,
2007). There were no other genes strongly associated with FA,
although mutations in four other genes, including spindle regulator cytoplasmic dynein (heavy chain), were statistically significant. However, the relevance of these genes is unclear, as they
tend to be large genes and the enrichment in FA tumors was
not very strong. Activating mutations in PIK3CA (p = 3310–3), followed by mutations in MAP3K1 (p = 8310–3), were enriched in the
low-FA tumors, although this is probably driven by the predominance of these mutations in luminal tumors that were enriched
in the low-FA tumor group (Figure 6). Thus, the only gene whose
mutation was strongly enriched in high-FA tumors was TP53.
We also compared the RNA expression data to identify the
genes that were overexpressed in FA tumors. All genes were
ranked from 1 being the most overexpressed in the high-FA
group to 18,000 being the most overexpressed in the lowFA group. We refer to the Breast FA100 gene set (BrFA100;
Table S2) as the 100 genes the were the most overexpressed
in the high-FA tumors. The BrFA100 contained 30 genes that
were also in the CIN70 list generated by independent methodology in multiple tumor types (Figure 3A; Table S3). Gene
ontology (GO) analysis demonstrated that the BrFA100 is highly
enriched in genes involved in the cell cycle, as the top two GO
terms were cell cycle (p = 5.3 3 10 81) and cell-cycle phase
(p = 1.3 3 10 77). ‘‘Cell cycle’’ is a broad GO term set that consists of 1,355 genes, so we asked which stage of the cell cycle
was best represented. Twenty of the top 30 GO terms represented mitotic segregation of chromosomes, suggesting that
genes controlling mitosis were driving this gene signature
(Table S4). We ran the BrFA100 gene sets through the STRING
database, which uncovered a highly noded network of 58 critical mitotic regulators (Figure 3B), including nine mitotic kinases
(AURKA, AURKB, TTK/MPS1, GSG2/Haspin, CHEK1, NEK2,
BUB1, CDK1, and MELK) and 13 kinetochore proteins (Table
S2). There was also a subset of cell-cycle regulators, but these
were dominated by the proteins that control the entry into
mitosis and contained proteins such as Cyclin B2/CCNB2,
Cyclin A2/CCNA2, CDK1, CKS1B, CDC25A, and CDC25C.
Finally, there were 17 genes associated with DNA replication
(DNA Rep), and 14 in DNA repair. These data corroborate the
CIN70 study (Carter et al., 2006) and greatly extend the idea
that aneuploidy (and, likely, CIN) is associated with overexpression of mitotic proteins.
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Figure 3. Regulators of Mitosis Are Overexpressed in Aneuploid Breast Tumors
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B

Fifty-six of the BrFA100 genes are found in at least 3 of 6 proliferation signatures (Figures 3A and S6A) (Cohen et al., 2013;
Fischer et al., 2016). We found that most proliferation signatures
contained about 10-fold enrichment of mitotic regulators, while
the CIN70 contained 18-fold enrichment and the BrFA100
contained over 25-fold enrichment (Figure 3C). We conclude
that aneuploid tumors overexpress a large number of genes
associated with proliferation, but there is stronger enrichment
for genes involved in mitosis.
Mitotic Transcriptional Regulators Drive the
Overexpression Patterns Seen in High-FA Tumors
To determine the mechanism of overexpressing the mitotic
genes, we asked whether any transcription factors were overexpressed in high-FA tumors. There were 8 transcription factors in
2762 Cell Reports 23, 2758–2769, May 29, 2018

The 100 most overexpressed genes in the highFA-ranking tumors (BrFA100) were identified by
comparing RNA expression data of the 100 highFA and low-FA tumors.
(A) The overlap of the BrFA100 genes, the CIN70
list, and genes present in 3–6 previously published
proliferation signatures (Multiple Proliferation
Signatures).
(B) STRING diagrams (http://string-db.org) of the
BrFA100 list show a highly noded grouping of
mitotic regulators, mitotic cell-cycle genes, and
DNA replication and repair proteins. The top 10 GO
terms of the BrFA100 list shows a strong enrichment of cell-cycle genes, which is driven by a high
M-phase gene enrichment (Table S4).
(C) Specifically, we plotted the relative fold
enrichment of genes in the chromosome segregation GO term in the BrFA100, CIN70, and six
different proliferation signatures.
See also Table S4.

our 100 proteins, and 6 of these control
the cell cycle (MYBL2, FOXM1, E2F1,
RBL1/p107, E2F7, and E2F8). Specifically, the oncogenes MYBL2, FOXM1,
and E2F1 (ranked 9th, 10th, and 38th)
were of interest due to their roles as
master transcriptional activators of genes
required for mitosis (Cao et al., 2011;
Grant et al., 2013; Sadasivam and
DeCaprio, 2013; Sadasivam et al., 2012).
Combining the target genes of the
DREAM, MMB, and FoxM1/MuvB transcriptional complexes accounts for 92 of
the 100 genes in the BrFA100 (Figure 4A)
(Fischer et al., 2016). Overexpression of
FOXM1, MYBL2, and E2F1 mRNA (z > 2)
correlated with FA scores (Figure 4B).
Overexpression of these three genes
was correlated with FA status in all four
breast tumor subtypes (Figure S5D).
There was also strong overlap of the
BrFA100 with genes identified in a meta-analysis as downregulated by TP53 (Figure 4C). The drivers of this gene signature
were shown to be DREAM, FOXM1, and MMB. The BrFA100
contained 91 of the top 486 genes that were overexpressed after
multiple treatments that downregulated tp53 function.
We mined publically available chromatin immunoprecipitation
followed by sequencing (ChIP-seq) datasets to examine whether
MYB2L, FOXM1, and E2F1 bind the promoters of the genes in
the BrFA100 lists (Cao et al., 2011; Grant et al., 2013; Sadasivam
et al., 2012). At least one of the three transcription factors binds
to the promoter of 82 of the 100 genes, and 49 of the BrFA100
genes are bound by at least two of the transcription factors (Figures 4D and S6B; Table S3). Twenty-two of the genes bound all
three transcription factors, including the three most overexpressed proteins TPX2, Plk1, and Aurora B/AURKB. For this

Figure 4. Mutations in TP53 and Overexpression of E2F1, MYB2L, and FOXM1 Are
Highly Associated in Breast Tumors
(A) The overlap of BrFA100 and target genes of
mitotic transcriptional regulation complexes
DREAM, FoxM1-MuvB/MMB, and Rb-E2F.
(B) The percentage of tumors in each group of 50
(ranked by aneuploid status) with 1, 2, or 3 of the
transcription factors MYBL2, FOXM1, and E2F1.
(C) Venn diagram of the overlap of the BrFA100
with the top 400 genes downregulated by TP53
(p53 expression score of less than 10, as listed in
Fischer et al., 2016).
(D) Venn diagram to show the overlap of ChIP-seq
datasets for E2F1, MYB2L, and FOXM1 with the
BrFA100 list. Gene lists are shown in Table S3.
(E) Association p values of TP53, E2F1, MYB2L,
and FOXM1 as individual pairs. p values
were obtained through Fisher exact tests with
Benjamini-Hochberg multiple test corrections.
(F) The percentage of tumors in each group of 50
that have a TP53 mutation and 1, 2, or 3 overexpressed transcription factors.
(G) Association of TP53, MYBL2, E2F1, and
FOXM1 in 960 human breast tumors of the TCGA.
Plots were generated at the cBioPortal (www.
cbioportal.org). (G’) The percentage of the 960
tumors with a TP53 mutation and either an
amplification (AMP) of the gene as defined by a
positive GISTIC score or an upregulation (Up) of
the mRNA as defined by a Z score > 2. TF,
transcription factor.
See also Table S3.

analysis, we used a subset of the FOXM1 ChIP-seq data that was
listed as the 270 ‘‘high-confidence’’ binding regions; interestingly, they contained 35 of the BrFA100 genes (exact hypergeometric probability, p < 9310–18). These data suggest that the
overexpression of the three transcription factors could drive
the overexpression of mitotic proteins that we find overexpressed in functionally aneuploid breast tumors. Interestingly,
E2F1 and FOXM1 were members of the 16 genes that were
not bound by any of the transcription factors, while MYBL2
was only in the E2F1 ChIP-seq set. This suggests that the
mechanisms that overexpress these oncogenes are independent of the events that cause the expression of the bulk of the
BrFA100 list.
We conclude that the BrFA100 signature can be explained by
the overexpression of the mitotic transcriptional regulators
MYBL2, FOXM1, and E2F1 and that this correlation is stronger
(91/100 genes) than general proliferation signatures (56/100).
A Two-Event Model for Aneuploidy in Breast Tumors
To determine whether TP53 works in conjunction with the mitotic
transcriptional regulators to generate FA, we asked whether the

tumors that contained mutated TP53
also overexpressed E2F1, FOXM1, and
MYBL2. The co-association of every
combination of TP53 mutations and the
overexpression of MYBL2, FOXM1, or
E2F1 are highly significant and provided in Figure 4E. This association suggests that these genes work together to provide an
advantage to tumor progression.
Overall, our bioinformatics suggest a two-event model for the
generation of aneuploidy in breast tumors. First, the overexpression of the oncogenes MYBL2, E2F1, and FOXM1 is the causative event of the chromosome missegregation, perhaps because
this event leads to the transcriptional overexpression of a large
number of mitotic regulators. Second, loss of tp53 is required,
which, we postulate, allows the cells that missegregate chromosomes to remain proliferative as suggested by the literature
(Hayashi et al., 2012; Jeon and Lee, 2013; Krzywicka-Racka
and Sluder, 2011; Santaguida et al., 2017; Uetake and Sluder,
2010). To estimate the number of aneuploid tumors that could
be explained by this two-hit model, we ranked the percentages
of tumors that had both TP53 mutations and overexpressed
the transcription factors according to our FA scores (Figure 4F).
Sixty percent of the 50 top tumors could be explained by this
two-hit model and the co-occurrence of TP53 mutations, and
overexpression of the mitotic transcription factors correlated
strongly with FA score. In Figures 4G and 4G’, we visualize the
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co-occurrence in over 900 breast tumors. This analysis also
shows the co-occurrence of TP53 mutations and overexpression
of one of the three transcription factors in 14.5% of all breast
tumors (Figure 4G’). It makes the point that these events may
have oncogenic potential beyond generating aneuploidy, since
there is a small set of tumors that either have TP53 mutated
without overexpressing mitotic transcriptional regulators or
that overexpress either MYBL2, FOXM1, or E2F1 without
mutating TP53. Overall, our data suggest that 39.6% of the
100 most aneuploid breast tumors become aneuploid because
they lose tp53 function and overexpress one of the transcriptional regulators of mitosis (Z > 2). If we increase the stringency
to requiring overexpression of 2 of the 3 transcription factors,
then approximately 25.4% of highly aneuploid tumors would
be explained by the model.
Overexpression of MYBL2, E2F1, and FOXM1 Generates
Lagging Anaphase Chromosomes in Non-transformed
Vertebrate Epithelial Tissues
We developed a system to connect the results of our bioinformatics approach to missegregation of chromatids in mitosis.
Our goal was to visualize the first mitosis after overexpression
of FoxM1, E2F1, and MybL2 in a non-transformed vertebrate
tissue. To do this, we used early embryos of the frog Xenopus
laevis. RNA encoding transcription factors can be injected into
embryos and translated into proteins; however, they are not
active during the first 12 division cycles that lack transcription
(Newport and Kirschner, 1982). After this time (8 hr postfertilization), the embryo undergoes the mid-blastula transition
(MBT) when transcription begins. Therefore, the immediate
action of transcription factors can be measured by visualizing
the mitoses of divisions directly after MBT (stages 8 and 9).
We injected mRNA encoding the human MYBL2, E2F1, and
FOXM1 transcription factors into two-cell Xenopus embryos.
For controls, we injected mRNAs with a stop codon inserted after
10 amino acids of each transcription factor. Western blot analysis of post-MBT embryo lysates confirmed the expression of
hMYBL2, hE2F1, and hFOXM1 in the embryos injected with
the functional RNAs (Figure 5A). The epithelial tissue above the
blastocoel (animal cap) can be easily dissected from the embryos without affecting normal cell divisions, providing an opportunity to collect relatively flat tissue from multiple embryos. The
animal cap tissue from FOXM1, MYBL2, and E2F1 (triple)-overexpressing or control RNA-expressing embryos was fixed,
stained with the DNA stain (TOPRO-3), and imaged on a confocal
microscope to visualize the chromosomes (representative
images are shown in Figure 5B). Individual chromatids between
segregating anaphase chromosome masses (lagging chromatid)
could be detected in 25% of all anaphase events in triple-overexpressing embryos, compared to less than 5% in singly injected control RNA (30 pg) and 8% in embryos injected with
three times the amount of control RNA (100 pg) (Figure 5C). In
embryos where RNA for only one of the transcription factors
was injected, there was an increase in the number of lagging
chromatids over controls, but in each case, these values were
also significantly lower than the triple-overexpressing clutchmates. To further characterize these mistakes in mitosis, we
also examined micronuclei in fixed animal cap tissue. Anaphase
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lagging chromosomes often become micronuclei in the subsequent interphase, because nuclear envelope formation happens
before the lagging chromatid joins the mass of segregating
chromatids (Zhang et al., 2013). Approximately 3.5% of tripleoverexpressing cells had visible micronuclei, while the singleoverexpressing embryos had micronuclei in 1.5%–2% of cells.
Again, the triple-injected embryos displayed a significantly
higher percentage of micronuclei than both controls or singly
overexpressing clutchmates (Figure 5D).
To confirm that the lagging chromatids and micronuclei were
caused by missegregation of chromosomes, we performed
time-lapse confocal microscopy of animal caps directly after
MBT. Moreover, we designed an experiment where the controls
and triple-injected cells could be visualized in the same animal
cap to control for frog-to-frog variability. In these experiments,
embryos were injected at the one-cell stage with RNA for a
GFP-tagged histone H2B to follow mitotic events. They were
then injected with either control RNA or the RNA encoding the
three transcription factors (FOXM1, E2F1, and MYBL2) in two
of the four cells of stage 3 embryos (Figures 5E and 5F). Fluorescent dextran was used to label the cells that were either
control or triply overexpressing, and there was no experimental
variability if the dextran was injected into control or triple-overexpressing cells (data not shown). After MBT, this treatment will
generate areas of the animal cap that contain both control and
triply overexpressing cells that can be distinguished by the fluorescent dextran. More than 20 videos of animal caps from separate in vitro fertilizations were made and analyzed. Again, we saw
a significantly higher level of abnormal divisions in the triply overexpressing half of animal caps, compared to the internal control
(Figure 5E). Embryos overexpressing only one of the transcription factors—in this case, the Xenopus version of MybL2—
showed an intermediate value of lagging chromatids during
mitosis, similar to the trend seen in fixed cap analysis (Figure 5F).
We conclude that overexpression of three oncogenic transcription factors in human breast tumors was sufficient to generate
aneuploidy in an nontransformed vertebrate epithelial tissue.
We also used the Xenopus system to determine whether preventing new translation of tp53 lowered chromosome segregation. However, this analysis is complicated by the fact that
tp53 protein is maternally loaded, and the protein is required
for early embryonic development (Wallingford et al., 1997). We
created two Morpholino oligonucleotides specific to Xenopus
TP53. While injection of either Morpholino had little effect on protein levels at stage 9, we saw a significant decrease in protein
levels by later stages (Figure S6C). We find that there is no increase in the number of lagging chromosomes or micronuclei
upon injection of TP53 Morpholino at stage 9 (Figure S6D).
These data are consistent with a large body of literature that
suggests TP53 mutations do not directly lower the fidelity of
mitosis (Santaguida et al., 2017; Soto et al., 2017; Thompson
and Compton, 2010; Uetake and Sluder, 2010).
Segregation of Human Breast Tumors by FA Status
Tumors of all four subtypes of breast cancer (basal-like, luminal
A, luminal B, and Her2 enriched) were represented in the 522
tumors analyzed by our computational method. All four of the
tumor subtypes contained both high- and low-FA-score tumors

Figure 5. Overexpression of hE2F1, hFOXM1, and hMYBL2 Is Sufficient to Generate CIN Phenotypes in Xenopus Embryos
(A) 2-cell-stage embryos were injected with either RNA containing stop codon after 33 nt ( ) or functional hE2F1, hFoxM1, and hMybL2 (+), as detected by
western blot.
(B) Representative images of TOPRO-stained normally dividing animal caps and two of the most common CIN phenotypes seen in triple-overexpressing
embryos. Yellow arrows indicate a lagging chromatid; blue arrow indicates a micronucleus.
(C and D) Quantification of lagging chromatids (C) and micronuclei (D) in control, triply overexpressing, or singly injected embryos through fixed-animal cap analysis.
(E) Representative time-lapse series of an animal cap expressing H2B:GFP with normally dividing control cells (co-injected with Ruby-Dextran) or CIN-like
phenotypes seen in neighboring triple-overexpressing cells. Blue arrows indicate abnormal divisions seen as lagging chromatids and micronuclei. Time points
chosen to show anaphase events.
(F) Quantification of lagging chromatid events as seen in time-lapse videos of control embryos, triply overexpressing embryos, and overexpression of only xMYBL2.
Full supplemental videos are available upon request. Scale bars represent 40 mm in all images. **p < 0.01; ***p < 0.001; ****p < 0.0001, one-way ANOVA and
Bonferroni post-test statistics,. Error bars represent ±SEM. 8 hpf, 8 hr post-fertilization.

(Figure 6A). Over one third of the high FA tumors were of the
Basal-like subtype, compared to the low-FA group, which only
contained 8 basal tumors. Luminal A tumors dominated the
low FA group. These data suggest that aneuploidy could be
used to further stratify tumors beyond current diagnostics.

It has been previously suggested that CIN is a predictor of prognosis. We generated Kaplan-Meier plots to compare the 200 highest and lowest FA-scoring tumors for all four tumor types. We did
not have enough statistical power to predict diagnosis for most
tumor subtypes. However, women with luminal B tumors fared
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Figure 6. Characterization of the Tumors Scored as High and Low FA
(A) Tumor subtype distribution of the 100 tumors scored as the highest FA and
lowest FA.
(B) Kaplan-Meier curve demonstrating that FA status indicates good prognosis
for the luminal B subtype of tumors.
(C) Our two-hit model for the generation and propagation of functional
aneuploidy; note that we do not indicate which event takes place first.

better if they had high FA scores (Figure 6B). The concept that patients with high levels of CIN have improved prognoses is consistent with a number of previous studies (Birkbak et al., 2011; Roylance et al., 2011, Zhang et al., 2016). We conclude that our
algorithm to measure FA has prognostic value for breast tumors.
DISCUSSION
We have used a bioinformatic approach to segregate breast
tumors in the TCGA that are highly aneuploid (both whole2766 Cell Reports 23, 2758–2769, May 29, 2018

chromosome loss and loss of large fragments of chromosomes)
from breast tumors of more normal ploidy. TP53 was the only
protein whose loss of function was strongly associated with
the high-FA tumors. In addition, our analysis argues that the
overexpression of oncogenes E2F1, FOXM1, and MYBL2, which
we find overexpressed specifically in high-FA tumors, is sufficient to lower the fidelity of chromosome segregation in vertebrate epithelial tissues. The frequency of anaphase lagging chromosomes was consistent with those predicted for optimal tumor
progression by CIN (Bakhoum and Compton, 2012). Not only are
E2F1, FOXM1, and MYBL2 oncogenes, but they also have a role
in non-transformed tissues as master controllers of the mitotic
transcriptional program. In fact, E2F1, FOXM1, and MYBL2
bind the promoters of a large percentage of the mitotic regulators that we also found overexpressed in high-FA breast tumors.
Bioinformatic Methods to Measure FA
There is an unmet need for a simple reliable measurement of
aneuploidy or CIN status for tumors (McGranahan et al., 2012;
Zasadil et al., 2016). Our data suggest that a combination of
TP53 mutation and overexpression of MYBL2, FOXM1, and
E2F1 may be diagnostically relevant. In addition, as tumor
sequencing becomes more prevalent, our bioinformatic method
provides the basis for a simple diagnostic test to measure FA in a
human tumor.
Our FA algorithm is an improvement in several ways on the
CIN70 algorithm, which has been useful and is the only available
technology to measure FA from genomic data (Carter et al.,
2006). First, our scoring is based on a direct measurement of
genome-wide tumor variation, not simply on correlations of
gene expression data. Second, the increase in publically available datasets allowed us to focus on mechanisms for breast
tumors where the CIN70 work required the mixing of tumor
types. Our methodology should be generalizable to other tumor
types. Third, we generated not only a score for approximating
CIN but also two plots that provide great insight into the subtleties and complexities of heterogeneity within the tumor. Fourth, it
is compatible with next-generation sequencing, which will be the
future of personalized medicine.
A Model for Generation of Aneuploidy in Breast Tumors
Our data support a two-event model for generation of FA (Figure 6C). First, TP53 is a CIN suppressor, and our data support
previous findings that the loss of tp53 function is strongly associated with aneuploidy in tumors (Li et al., 2010; Thompson and
Compton, 2010). Second, overexpression of mitotic transcriptional regulators drive the missegregation of chromosomes in
mitosis. While it is unlikely that this is the only mechanism to
generate CIN, we calculate that this two-step mechanism may
act in about 40% of the most aneuploid breast tumors and
15% of all breast tumors.
Our data are consistent with a growing body of literature reporting that an important role of tp53 is to trigger senescence
or cell-death pathways after the missegregation of chromosomes (Hinchcliffe et al., 2016; Lambrus et al., 2015;
Orth et al., 2012; Uetake and Sluder, 2010), and we suggest
that aneuploidy or CIN usually develops after this pathway is
lost. The strong co-association of TP53 mutations with the

overexpression of MMB/FOXM1 mitotic regulators has also
been previously shown; in fact, MMB/FOXM1 drives the transcriptional responses that are found after tp53 loss. Our data
suggest that the evolutionary advantage of this co-association
would be the generation of genomic instability through CIN,
although it is formally possible that the MMB/FOXM1 mitotic regulators provide a function that allows tumors to survive the loss
of tp53 without causing aneuploidy. To distinguish between
these models, we tested whether overexpression of MYBL2,
FOXM1, and E2F1 generated CIN phenotypes. In untransformed
Xenopus embryonic tissue, mitotic transcriptional regulator
overexpression was sufficient to generate anaphase lagging
chromatids at rates comparable to those of CIN in tumors,
providing a strong causal link between mitotic transcriptional
regulation and CIN.
We don’t know how E2F1, FOXM1, and MYBL2 overexpression lowers the fidelity of mitosis, but the simplest model is
that they drive the overexpression of a large number of mitotic
regulators, which lowers the robustness of mitotic pathways.
For example, the proteins involved in the resolution and prevention of merotelic kinetochore microtubule attachments (Aurora
B, Borealin, Survivin, Bub1, MPS1, Plk1, Sgo1, and Ndc80) are
all regulated by E2F1 and FOXM1/MMB and overexpressed in
human CIN breast tumors, which could be the underlying cause
of lagging anaphase chromatids. It is also consistent with recent
studies that FOXM1 is a central regulator of kinetochore gene
transcription and the fact that centromere gene expression can
predict patient outcomes (Banerjee et al., 2014; Laoukili et al.,
2005; Thiru et al., 2014; Zhang et al., 2016).
We suggest that the Xenopus animal cap system is an ideal
system to assay the development and the consequences of FA
because it combines (1) very low background missegregation
rates with (2) outstanding observation of mitotic events by microscopy and (3) the employment of a non-transformed vertebrate
tissue that would become the skin and neural tissues of a frog,
if not manipulated; (4) the ability to rapidly manipulate these
events by loss- and gain-of-function methodologies; and
(5) the ability to quickly replace loss-of-function experiments
with mutants.

reads that align to that base in the reference genome. In high-FA tumors,
numerous LOH and CNA events will cause VAF deviations at large numbers
of SNPs across the entire genome, resulting in markedly broader VAF distributions that are obvious from genome-wide VAF histograms (as in Figure 1). The
FA score is derived from the SD of VAF measurements in the tumor exome
sequencing data across all heterozygous germline SNPs.
Quantification and Statistical Analysis
All statistical tests are specified in the text or figure legends, and details can be
found in the Supplemental Experimental Procedures.
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Xenopus Embryo Injection and Analysis
Capped RNA was diluted to 25 pg/nL at 2.5-nL injections, with a final concentration of 30–100 pg per embryo. Animal caps were cut and visualized at
stages 8–9. Embryos were injected with transcription factor (TF)-specific or
control RNAs (dual stop codons 10 amino acids downstream of the
translational start site); for live-cell imaging, embryos were coinjected with
nuclear label-H2B:GFP in PCS2+ vectors as described earlier in the text.
Scoring of FA from Exome Sequencing Data
The FA score was calculated from tumor exome sequencing data by
measuring the variant allele frequency (also known as ‘‘allele balance’’)
distribution at heterozygous germline SNPs, where heterozygous germline
SNPs are defined by variant calls and genotypes in the matched normal
data. The variant allele frequency (VAF) of each SNP is calculated by dividing
the number of reads containing the alternate SNP allele by the total number of
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Supplemental Experimental Procedures:
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kep9v@virginia.edu)

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Xenopus Embryo preparation and injection
Embryos were obtained from X. laevis females which were injected with 800 U of human chronic gonadotropin
into the dorsal lymph sac 16h before use. Eggs were laid into 1/3x MBS (88 mM NaCl, 1 mM KCl, 0.7 mM
CaCl2, 1mM MgSO4, 5mM HEPES (pH7.8), 2.5 mM NaHCO3, pH 7.8) and fertilized by adding macerated
testes. At 20 min after fertilization, embryos were dejellied in 2% cysteine (in 1/3 MBS, pH 8.0) and rinsed
several times with 1/3x MBS. Completely dejellied embryos were maintained in 1/3x MBS at RT until
microinjection. Injections were performed in 5% Ficoll solution in 1x MBS at one-cell to four-cell stages
depending on the experiment. Half an hour after the last injection, embryos were returned to 1/3xMBS. DNA
plasmids containing human E2F1 (HA-E2F-1 wtpRcCMV) and MybL2 (pCDNA3) were purchased from
Addgene. The FOXM1 clone was obtained from the human ORFeome and cloned into pCSF107mT through
Gateway cloning. The control RNAs were generated by inserting a stop codon 33 nucleotides after the start
site of transcription for each of the plasmids of E2F1, MybL2, and FOXM1. The primers used to generate these
clones are as follows:
E2F1 5’GCGGCCCATGATAGCCGGCGCTGGAG,
R:CTCCAGCGCCGGCTATCATGGGCCGC
FoxM1: 5’CGTCGGCCACTGATTTAGTAAAGACGGAGGCTGC,
R:GCAGCCTCCGTCTTTACTAAATCAGTGGCCGACG
MybL2: 5’CGCTGCGAGGATCTGTAGTAGCTGCACTACCAGGACACAG
R:CTGTGTCCTGGTAGTGCAGCTACTACAGATCCTCGCAGCG.
Capped RNA was generated using mMESSAGE mMACHINE SP6 or T7 kit (AM1344, AM1345; Thermo
Fischer Scientific). A dilution to 25pg/nl at 2.5nl injection, with a final concentration of 30-100pg per embryo,
gave phenotypes in the triply-over expressing embryos and no discernable phenotype in the control RNA
injections, therefore this concentration was used in all experiments. For live cell imaging embryos were
coinjected at 2-cell stage with a membrane label-GAP43:RFP and nuclear label-H2B:GFP in PCS2+ vectors.
As directed by Gene Tools LLC, the Morpholino stock was made at 1mM in diH2O so that when injected into
the embryo there was a final concentration of 5-10uM in the embryo, a concentration that has been validated
through multiple other Morpholino studies and shows no off-target toxicities or effects. The sequences are as
follows:
Translation Blocking: 5’ CCATGCCGGTCTCAGAGGAAGGTTC 3’
Splice Blocking: 5’ GGGACTCACCGTGCAGGTAACAGAC 3’
METHOD DETAILS
Scoring of FA from exome sequencing data
The FA score was calculated from tumor exome sequencing data by measuring the variant allele frequency
(also known as “allele balance”) distribution at heterozygous germline single nucleotide polymorphisms
(SNPs), where heterozygous germline SNPs are defined by variant calls and genotypes in the matched normal
data. The variant allele frequency (VAF) of each SNP is calculated by dividing the number of reads containing
the alternate SNP allele by the total number of reads that align to that base in the reference genome.
Heterozygous germline SNPs are expected to be found at a VAF of approximately 0.5, with minor deviations
occurring due to stochastic sampling of chromosomes during exome sequencing. Loss of heterozygosity (LOH)
events and copy number alterations (CNA) cause VAF deviations at heterozygous SNPs by altering the copy
number of one SNP allele relative to the other SNP allele. For example, an LOH event that is fixed among
tumor cells will result in heterozygous SNPs within the altered genomic segment to have VAF values of 0 or 1
(depending on which allele is lost), with subclonal alterations causing intermediate values. In high-FA tumors,
numerous LOH and CNA events will cause VAF deviations at large numbers of SNPs across the entire
genome, resulting in markedly broader VAF distributions that are obvious from genome-wide VAF histograms
(as in Figure 1). The FA score is derived from the standard deviation of VAF measurements in the tumor
exome sequencing data across all heterozygous germline SNPs.
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Immunofluorescence and Live Imaging
Fixed cell immunofluorescence microscopy was performed on St. 8.5-9 embryos (approximately 8-9 hours post
fertilization) that were fixed overnight at -20C in Dent’s solution (80% methanol, 20% DMSO). They were
postfixed in methanol for 9h or overnight at -20C. Embryos were then hydrated and dissected in Tris-buffered
saline (150mM NaCl, 50mM Tris; pH 7.4) with 1% SDS detergent (TBS and Tween 20 [TBST]. The dissected
caps were subjected to a DNA stain (TOPRO 3, 1:20000 dilution) for 30- 60 min at RT, and dehydrated in
Methanol overnight. Pre-imaging, fixed caps were cleared in Murray’s solution (2:1 Benzyl Benzoate, Benzyl
Alcohol) 15- 30 min, mounted on slides (Histomount, Life Technologies). Images were taken by Axiovert 200
microscope (Carl Zeiss) with PerkinElmer-RS spinning disk confocal system illuminated by a krypton/argon
laser, using a 40x or 60x oil immersion objective (NA 1.4; Carl Zeiss), with images acquired by an electron
multiplying charge coupled device camera (Hamamatsu C9100) using Velocity software. For live imaging
experiments, capped RNA was generated using an SP6 mMessage mMachine kit (Ambion). Xenopus laevis
embryos were injected while suspended in 5% Ficoll solution at 2-cell stage with 50-150pg of RNA. To
visualize mitotic events embryos were co-injected membrane label (GAP43:RFP) and nuclear label
(H2B:GFP). Triple mutants were additionally co-injected with 30pg of each of the transcription factors
overexpressed, whereas the controls were injected with an equal concentration of control RNA. At NF stage 8,
embryos were devitellined and the animal cap portion was removed by microsurgery and sandwiched between
coverslips before imaging. A time-lapse movie of the layer of cells that make up the blastocoel roof was made
on a Zeiss 780 Confocal Microscope with the 25x objective and a framing rate of 30 s. We thank Robert Rotzin
for help with the live imaging acquisition. To quantify chromosome instability phenotypes in animal caps, we
assessed every anaphase event that could be clearly visualized and scored it as having an anaphase lagging
chromosome (a chromosome clearly left at the area of the metaphase plate without significant stretching of
chromatin toward either pole), a multipolar anaphase (chromosomes segregating in more than 2 directions),
anaphase bridging (chromatin stretched between the segregating anaphase masses) or normal anaphase
segregation (controls n=187 in 18 movies, triple injection n=436 in 12 movies). Movies included anaphase
events in stages 8-9.5. Statistical significance was measured using a one-way ANOVA with a Bonferonni posttest.
Embryos lysates and immunoblotting
Embryos lysates for western blotting were collected at stages 7, 8, 9 for both control and triply-overexpressing
embryos as described in [S5]. Blots were stained with a 1:500 dilution of anti- E2F1 (clones KH20 &KH95,
mixed mouse monoclonal IgGs, 05-379; Millipore), anti-FoxM1 (G- 5: sc-376471, Santa Cruz
Biotechnology,Inc.), anti- MybL2 (phospho T487, ab76009; Abcam), p53 X-77, MA1-12549, Thermo Fisher
Scientific), and anti-α-tubulin (Dm1α, 1:2000 dilution) used as a loading control. Secondary antibodies
conjugated to HRP at a 1:10,000 dilution were visualized using Amersham ECL Prime Western Blotting
Detection Reagent, (GE Healthcare) and imaged with Chemi Doc Bio-Rad system.
QUANTIFICATION AND STATISTICAL ANALYSIS
Identification of significantly mutated genes in high- vs. low-FA tumors.
For mutation burden analysis, we used the official somatic mutation calls from the Level 2 Illumina exome
sequencing VCF files in the TCGA project database, which are derived from precisely the same exome
sequencing datasets that we used to measure FA. We then used the VAAST software package (version 1.0.4)
[S1]to identify genes that were significantly mutated in the 100 tumors with the highest FA scores relative to the
100 tumors with the lowest FA scores using the following command line parameters: “-m lrt--codon_bias --gp
10000 -r 0.001”. We then performed the reverse enrichment experiment to identify genes that were significantly
mutated in the 100 tumors with the lowest FA scores relative to the 100 tumors with the highest FA scores
using the same parameters. To test whether the number of TP53 mutations was linearly correlated with
aneuploidy ranking, we performed a linear-by-linear association test using R. We performed separate tests for
the most aneuploid (Rank 1-250) and least aneuploid (Rank 251-522) tumors binned into groups of 50.
Identification of genes that are overexpressed in high-FA tumors (the BrFA100 gene list)
To identify genes whose expression was correlated with FA, we calculated the Pearson correlation coefficient
between the highest and lowest FA scored tumors described above and gene-level RNA expression values
obtained from TCGA. This correlation-based approach is identical to that previously used to identify the CIN70
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gene list [S2] although we note that the prior study used a different CIN scoring method and RNA expression
array platform.
DATA AND SOFTWARE AVAILABILITY
Bioinformatic analysis
Co-association analysis was performed at the CBioPortal Web site by inputting the four genes and determining
if there were any associations of either mutations or RNA expression patterns. Venn Diagram in figure 4D was
generated by inputting the referenced gene sets into the Venn diagram maker at Bioinformations and
Evolutionary genomics at Ghent (http://bioinformatics.psb.ugent.be/webtools/Venn/). GO analysis was
performed at http://www.geneontology.org/page/go-enrichment-analysis [S3]. String network diagram was
produced using the String Webportal tool (http://string-db.org) limiting interactions to actions with the highest
confidence ratios[S4]. To generate the masks that highlight the genes involved in mitosis, cell cycle and DNA
replication and began with G0 terms but also performed manual curations based on pubmed searches using
the gene and associated processes. The masks were generated by hand to include these manually curated
lists. Contact Ira Hall (ihall@wustl.edu) for Matlab code to generate Allele Frequency Plots.
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RESOURCES TABLE
REAGENT or RESOURCE
Antibodies
Anti-E2F1 (clones KH20 & KH95)
Anti-MybL2 phospho T487
Anti-FoxM1
Anti-alpha-tubulin
Anti-p53
Biological Samples
Chemicals, Peptides, and Recombinant Proteins
Dextran, tetramethylrhodamine (and fluorescein),
70,000 MW, Lysine Fixable
TO-PRO-3 Stain
Critical Commercial Assays
mMessage mMachine
Deposited Data
Experimental Models: Cell Lines
Experimental Models: Organisms/Strains
Xenopus laevis Embryos

Recombinant DNA
pCS2H2B-GFP/pCS2H2B-RFP

pCS2GAP43-RFP/pCS2GAP43-GFP
pCDNA3-MybL2, HA-E2F-1-wt-pRcCMV
pCSF107mT-FoxM1
Sequence-Based Reagents
Primers for generating Control RNAs
Full sequences in supplemental materials
Xenopus p53 Morpholinos
Full sequences in supplemental materials

SOURCE

IDENTIFIER

Milipore
Abcam
Santa Cruz
Abcam
ThermoFisher

05-379
Ab76009
Sc-376471
Ab7291
MA1-12549

ThermoFisher

D1818, D1823

ThermoFisher

T3605

ThermoFisher

AM1344, AM1345

Nasco

In house colony,
Dr. R Keller
laboratory

Stukenberg Lab,
developed at
Wallingford Lab,
University of Texas,
Austin
Ray Keller Lab
Addgene
humanORFeome,
XenopusORFeome
Invitrogen, Fisher
Scientific
Gene Tools, LLC.

Xp53-TrBl: GFP
MO, Xp53SpliceMO: GFP

Software and Algorithms
VAAST version 1.0.4
CBioPortal
Bioinformations and Evolutionary genomics
http://bioinformatics.psb.ugent.be/webtools/Venn/
http://biovenn.nl
Other
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Supplemental Figures and Legends.
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Figure S1. Why aneuploidy changes the AAF of heterozygous alleles (Related to Figure 1). We calculate the
AAF of a SNP by the number of next gen sequence reads of the alternate allele divided by the number of total
reads for that locus. All heterozygous SNPs will generate an AAF around 0.5 in a normal sample. However, in
the theoretical case where there is an extra chromosome in about half the cells in the tumor then the
heterozygous SNPs on that chromosome will both increase (if they are the alternate allele) or decrease if they
are the allele on the reference genome. The AAF is dependent upon both the amount of aneuploidy (in this
case 3 chromosomes) and the percentage of the cells in the tumor that have that aneuploidy (50% of the cells).
In this theoretical case, the AAF for all the heterozygous SNPs on the extra chromosome will be either 0.42 or
0.58.

6

7

Figure S2. The pipeline used to measure aneuploidy in tumors (Related to Figure 1). Germline heterozygous
SNPs are identified from breast cancer TCGA exome data based on their presence in paired normal samples.
After calculation of alternate allele frequencies (AAFs; top plots), heterozygous SNPs are defined as those with
an AAF>=0.25 and AAF<=0.75 in the normal sample (middle plots). When one generates histograms
quantifying the number of initially heterozygous SNPs with various AAF the distribution in the tumor samples
then one can detect aneuploidy and tumor heterogeneity by two different mechanisms. First the central peak
around AAF broadens. Second, if there is LOH of chromosomes in a large percentage of the cells then all of
the SNPs now generate AAF peaks at 0 or 1, which generate peaks that are outside the central peak. We also
generate a second plot for each tumor (bottom plots). In these plots the AAF is on the Y-axis and Chromosome
position is on the X-axis and each SNP is given a single dot. The tumor used in this example was scored as
having the 14th most functional aneuploidy of 522 tumors.
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Figure S3. Method of scoring FA according to the AAF plots (Related to Figures 1,2). We generated line
graphs that represent the shape of the associated AAF plot and then calculated a standard deviation of the
associated curve, as visualized by the width of the peaks.
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Figure S4. AAF histograms of the Normal (non-transformed) samples (Related to Figure 1). Here we show the
matched normal samples from the patients whose tumors are shown in Figure 1A. The ranking of each tumor
is shown as the number in the top left corner of each histogram.
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Figure S5. Method of distinguishing between whole and partial LOH events (Related to Figure 1 and 4). A) We
manually visualized the chromosome position vs. AAF plots. We scored every chromosome of every tumor by
determining if there were two major peaks maxima below AAF 0.25 and greater than 0.75 that spanned along
a chromosome. These AAF ratios were chosen to rule triploidization events that generated peaks at 0.33 and
0.67. Note that it is possible that we miscall a chromosome LOH event if there are more than 4 times the
number of one parental chromosome over its homolog. Each chromosome was scored as: 1) entire
chromosome that had a split peak across all positions for a chromosome was scored as “Whole Chromosome
LOH”, if we could find splitting of some regions of chromosome but others with allele frequencies between 0.25
and 0.75 it was scored as “Partial Chromosome LOH”, if we could not find any splitting of peaks along a
contiguous region of a chromosome the tumor was scored as “No Chromosome LOH”. The number of
chromosomes with an LOH events comprising a whole chromosome (B) in breast tumors correlates with the
FA score (similar to Fig 1D). R2 value was generated by fitting the points to a linear regression in Excel. C)
Plot to show that partial chromosome events correlated with tumor ranking although this correlation was lower
than either the total number of LOH events or the whole chromosome events. R2 value was generated by
fitting the points to a second order polynomial curve in Excel. D) TCGA RNA-seq gene expression data from
primary solid tumor sample of breast cancer patients for MYBL2, E2F1, and FOXM1 was compared for the 200
highest and 200 lowest FA scoring tumors. We stratified the data by different subtypes of breast cancer
patients, including Basal, HER2+, Luminal A, and Luminal B and performed a T-test between high FA and low
FA TCGA breast cancer patients, and report the p-value.
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Figure S6. BrFA100 is significantly from proliferation signatures (Related to Figure 4) and xtp53 knockdown
alone is not responsible for Xenopus phenotypes (Related to Figure 5). The overlap of the BrFA100, CIN70
and each of 6 different proliferation signatures are shown through Venn Diagrams (A). Gene lists are available
in Table S3. (B) A different visual representation of the overlap of the BrFA100 and the ChIP-Seq data sets for
E2F1, FoxM1, and MybL2. (C) Western Blot analysis of p53 Morpholino injected Xenopus embryos at Stage 9
and Stage 22 shows that a significant decrease in tp53 protein level is not seen until much later than when
most of our in vivo experiments take place. This is why we do not see an increase in the number of micronuclei
or lagging chromosomes in p53MO injected embryos (D) (n=30 for controls, n=15 for p53MO experiments).
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